Fifth Circuit appears supportive of FTC in Illumina appeal

A conservative-leaning federal appellate court appeared relatively open to the Federal Trade Commission’s order finding Illumina’s acquisition of Grail would likely harm competition for cancer-screening tests during oral arguments on Tuesday.